Results 91 to 100 of about 20,409 (197)

Mechanisms and management of pegylated interferon-α toxicity in chronic hepatitis B. [PDF]

Front Immunol
Zhu L, Peng F, Pi D, Lu J.
europepmc   +1 more source

Sustained HBsAg clearance induced by pegylated interferon α-2b in HBeAg-negative patients with low baseline HBsAg. [PDF]

Front Cell Infect Microbiol
Wen C, He T, Zha G, Li A, Wang Z, Zhou Z, Cai D, Zhang D, Peng M, Shi X, Ren H.   +10 more
europepmc   +1 more source

Efficacy of pegylated interferon alpha in treating postpartum women with chronic hepatitis B virus infection: a multicenter prospective study. [PDF]

Front Cell Infect Microbiol
Gong H, Liu M, Zhang X, Sun W, Deng H, Liu W, Wu Y, Deng G, Xia J, Mao Q, Jiang L.   +10 more
europepmc   +1 more source

Pegylated Interferon-based Treatment Improves Response Rates in Immune-tolerant Patients with Chronic Hepatitis B: A Prospective Trial. [PDF]

J Clin Transl Hepatol
Liu M, Zuo L, Zhang Y, Bu B, Xiao A, Zhu L, Ma X, Wang Y, Yue W, Geng J, Xia X.   +10 more
europepmc   +1 more source

Rapid Hematological and Molecular Response to Pegylated Interferon in WHO-Defined Pre-Fibrotic Myelofibrosis. [PDF]

Cancers (Basel)
Machherndl-Spandl S, Kiehberger M, Sygulla V, Kaynak E, Zach O, Webersinke G, Gruber-Rossipal C, Beham-Schmid C, Maier E, Strassl I, Clausen J, Nikoloudis A, Schimetta W, Rumpold H, Buxhofer-Ausch V.   +14 more
europepmc   +1 more source

Safety evaluation and toxicokinetics of repeated inhalation exposure to pegylated interferon α-2b. [PDF]

Front Pharmacol
Ji C, Ji X, Li H, Wang Q.
europepmc   +1 more source

Statins enhance the efficacy of pegylated interferon-alfa2 in Philadelphia-negative chronic myeloproliferative neoplasms. [PDF]

Blood Adv
Davidsen ID, Larsen MK, Löffler L, Skov V, Kjær L, Knudsen TA, Sørensen AL, Christensen SF, Cordua S, Eickhardt-Dalbøge CS, Kristiansen MH, Ellervik C, Wienecke T, Hasselbalch HC.   +13 more
europepmc   +1 more source

Response-guided bulevirtide ± pegylated interferon alfa-2a: Long-term outcomes observed in the nationwide Austrian hepatitis D cohort study. [PDF]

JHEP Rep
Schwarz M, Hintersteininger M, Schwarz C, Panzer M, Pfisterer N, Loschko N, Hartl L, Dorn L, Laferl H, Trauner M, Stättermayer AF, Mandorfer M, Graziadei I, Maieron A, Moschen A, Aigner E, Stadlbauer V, Madl C, Aberle SW, Zoller H, Gschwantler M, Reiberger T, Jachs M.   +22 more
europepmc   +1 more source

Machine learning prediction of functional cure to pegylated interferon-alpha therapy in two HBV populations: Advantaged populations and HBeAg-negative patients. [PDF]

Virulence
Li J, Li H, Lin C, Jiang R, Wang L, He Y, Yang X, Gong K, Xun Z, Zheng Q.   +9 more
europepmc   +1 more source

The impact of JAK2^V617F variant allele frequency in MPN patients following PEGylated interferon alpha discontinuation. [PDF]

Br J Haematol
Brown R, Bennett R, Crean C, Hindley A, McGimpsey J, Cunningham N, Niblock A, McPherson S, Boyd K, Foy A, Graham C, Greenfield G, McMullin MF, Catherwood MA.   +13 more
europepmc   +1 more source